Patents by Inventor Hartmut Ehrlich

Hartmut Ehrlich has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11826372
    Abstract: An antitumor pharmaceutical combination includes (i) a compound ABX196 and (ii) at least one chemotherapeutic agent and/or at least one immunotherapeutic agent, for use in the treatment of cancer.
    Type: Grant
    Filed: December 6, 2021
    Date of Patent: November 28, 2023
    Assignee: ABIVAX
    Inventors: Sandrine Crabe, Didier Scherrer, Hartmut Ehrlich, Philippe Pouletty
  • Patent number: 11793855
    Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, an identify a TFPI-binding compound.
    Type: Grant
    Filed: January 14, 2019
    Date of Patent: October 24, 2023
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Michael Dockal, Rudolf Hartmann, Markus Fries, Friedrich Scheiflinger, Hartmut Ehrlich, Ulrich Reineke, Frank Osterkamp, Thomas Polakowski
  • Publication number: 20230142547
    Abstract: The treatment or prevention of a Coronaviridae infection, and conditions related thereto; in particular a Coronaviridae infection in humans. In particular, the compounds, pharmaceutical compositions and medicaments for treating and/or preventing a Coronaviridae infection and/or its long-term consequences. The uses and methods for assessing a Coronaviridae infection or the efficacy of a treatment of such infections.
    Type: Application
    Filed: March 19, 2021
    Publication date: May 11, 2023
    Applicant: ABIVAX
    Inventors: Jamal TAZI, Hartmut EHRLICH, Philippe POULETTY, Julien SANTO, Didier SCHERRER
  • Publication number: 20220193089
    Abstract: An antitumor pharmaceutical combination includes (i) a compound ABX196 and (ii) at least one chemotherapeutic agent and/or at least one immunotherapeutic agent, for use in the treatment of cancer.
    Type: Application
    Filed: December 6, 2021
    Publication date: June 23, 2022
    Applicant: ABIVAX
    Inventors: Sandrine CRABE, Didier SCHERRER, Hartmut EHRLICH, Philippe POULETTY
  • Publication number: 20220145406
    Abstract: Biomarkers and uses thereof in monitoring, assessing, and/or treatment of viral infections, or inflammatory diseases, disorders, or conditions, or cancer.
    Type: Application
    Filed: December 19, 2019
    Publication date: May 12, 2022
    Applicants: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITÉ DE MONTPELLIER
    Inventors: Philippe POULETTY, Hartmut EHRLICH, Didier SCHERRER, Jamal TAZI, Laurent MANCHON
  • Patent number: 11278552
    Abstract: An antitumor pharmaceutical combination includes (i) a compound ABX196 and (ii) at least one chemotherapeutic agent and/or at least one immunotherapeutic agent, for use in the treatment of cancer.
    Type: Grant
    Filed: September 14, 2017
    Date of Patent: March 22, 2022
    Assignee: Abivax
    Inventors: Sandrine Crabe, Didier Scherrer, Hartmut Ehrlich, Philippe Pouletty
  • Publication number: 20220071985
    Abstract: A compound of formula (Ib?) or anyone of its metabolites or a pharmaceutically acceptable salt thereof for use for treating and/or preventing cancer and/or dysplasia wherein R is independently hydrogen, halogen, —CN, hydroxyl, (C1-C3)fluoroalkyl, (C1-C3)fluoroalkoxy, (C3-C6)cycloalkyl, —NO2, —NR1R2, (C1-C4)alkoxy, phenoxy, —NR1—SO2—NR1R2, —NR1—SO2—R1, —NR1—C(?O)—R1, —NR1—C(?O)—NR1R2, —SO2—NR1 R2, —SO3H, —O— SO2—OR3, —O—P(?O)(OR3)(OR4), —O—CH2—COOR3, (C1-C3)alkyl, said alkyl being optionally mono- or di-substituted by a hydroxyl group, a -A-(CH2)m—B—NRaRb group, or a —(O—CH2—CH2)p—O—Ra group. The present disclosure also relates to a compound of formula (IVb?) or a pharmaceutically acceptable salt thereof for use for treating and/or preventing cancer and/or dysplasia.
    Type: Application
    Filed: December 19, 2019
    Publication date: March 10, 2022
    Applicants: ABIVAX, INSTITUT CURIE, UNIVERSITE DE MONTPELLIER, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Philippe POULETTY, Hartmut EHRLICH, Didier SCHERRER, Jamal TAZI
  • Patent number: 11266667
    Abstract: The compound ABX196 and pharmaceutical compositions including ABX196 are used in the treatment of bladder cancer.
    Type: Grant
    Filed: September 13, 2018
    Date of Patent: March 8, 2022
    Assignee: ABIVAX
    Inventors: Sandrine Crabe, Didier Scherrer, Hartmut Ehrlich, Philippe Pouletty
  • Publication number: 20220023324
    Abstract: A compound of Formula (I): or anyone of its metabolites or a pharmaceutically acceptable salt thereof, for use for treating and/or preventing an inflammatory disease, disorder or condition, wherein each R is independently hydrogen, halogen, —CN, hydroxyl, (C1-C3)fluoroalkyl, (C1-C3)fluoroalkoxy, (C3-C6)cycloalkyl, —NO2, —NR1R2, (C1-C4)alkoxy, phenoxy, —NR1—SO2—NR1R2, —NR1—SO2—R1, —NR1—C(?O)—R1, —NR1—C(?O)—NR1R2, —SO2—NR1R2, —SO3H, —O—SO2—OR3, —O—P(?O)—(OR3)(OR4), —O—CH2—COOR3, (C1-C3)alkyl; each R? is independently hydrogen, (C1-C3)alkyl, hydroxyl, halogen, —NO2, —NR1R2, morpholinyl, morpholino, N-methylpiperazinyl, (C1-C3)fluoroalkyl, (C1-C4)alkoxy, —O—P(?O)—(OR3)(OR4), —CN, a —NH—SO2—N(CH3)2 group, or other groups and further relates to A compound of formula (IV): or a pharmaceutically acceptable salt thereof, for use for treating and/or preventing an inflammatory disease, disorder or condition, wherein V, Z, R, R?, n, and n? are as described above.
    Type: Application
    Filed: December 19, 2019
    Publication date: January 27, 2022
    Applicants: ABIVAX, INSTITUT CURIE, UNIVERSITE DE MONTPELLIER, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Philippe POULETTY, Hartmut EHRLICH, Didier SCHERRER, Jamal TAZI
  • Publication number: 20210300997
    Abstract: The present invention is based on the discovery of polyclonal IgG's ability to promote Schwann cell maturation, differentiation, and myelin production. Methods for treating non-idiopathic, demyelinating peripheral neuropathies in mammals, where the neuropathy is not immune-mediated or infection-mediated, through the administration of polyclonal IgG are provided. Types of demyelinating peripheral neuropathies treatable with the present invention include peripheral nerve trauma and toxin-induced peripheral neuropathies. Alternatively, a composition of polyclonal IgGs can be applied directly to a peripheral nerve cell to induce maturation, differentiation into a myelinating state, and myelin expression or promote cell survival.
    Type: Application
    Filed: June 14, 2021
    Publication date: September 30, 2021
    Inventors: Patrick Küry, Nevena Tzekova, Hans-Peter Hartung, Corinna Hermann, Birgit Maria Reipert, Hans-Peter Schwarz, Hartmut Ehrlich, Sebastian Bunk
  • Publication number: 20210187105
    Abstract: The present invention pertains to anti-MIF antibodies, in particular their use in combination with glucocorticoids, in the treatment of glucocorticoid receptive diseases.
    Type: Application
    Filed: December 31, 2020
    Publication date: June 24, 2021
    Inventors: Randolf Kerschbaumer, Dirk Voelkel, Friedrich Scheiflinger, Hartmut Ehrlich
  • Patent number: 11001613
    Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, and/or treat a blood coagulation disorder in a subject.
    Type: Grant
    Filed: August 18, 2017
    Date of Patent: May 11, 2021
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Michael Dockal, Hartmut Ehrlich, Friedrich Scheiflinger, Ulf Reimer, Ulrich Reineke, Thomas Polakowski, Eberhard Schneider
  • Publication number: 20200230163
    Abstract: The compound ABX196 and pharmaceutical compositions including ABX196 are used in the treatment of bladder cancer.
    Type: Application
    Filed: September 13, 2018
    Publication date: July 23, 2020
    Inventors: Sandrine CRABE, Didier SCHERRER, Hartmut EHRLICH, Philippe POULETTY
  • Publication number: 20200216518
    Abstract: The present invention is based on the discovery of polyclonal IgG's ability to promote Schwann cell maturation, differentiation, and myelin production. Methods for treating non-idiopathic, demyelinating peripheral neuropathies in mammals, where the neuropathy is not immune-mediated or infection-mediated, through the administration of polyclonal IgG are provided. Types of demyelinating peripheral neuropathies treatable with the present invention include peripheral nerve trauma and toxin-induced peripheral neuropathies. Alternatively, a composition of polyclonal IgGs can be applied directly to a peripheral nerve cell to induce maturation, differentiation into a myelinating state, and myelin expression or promote cell survival.
    Type: Application
    Filed: October 18, 2019
    Publication date: July 9, 2020
    Inventors: Patrick Küry, Nevena Tzekova, Hans-Peter Hartung, Corinna Hermann, Birgit Maria Reipert, Hans-Peter Schwarz, Hartmut Ehrlich, Sebastian Bunk
  • Patent number: 10494418
    Abstract: The present invention is based on the discovery of polyclonal IgG's ability to promote Schwann cell maturation, differentiation, and myelin production. Methods for treating non-idiopathic, demyelinating peripheral neuropathies in mammals, where the neuropathy is not immune-mediated or infection-mediated, through the administration of polyclonal IgG are provided. Types of demyelinating peripheral neuropathies treatable with the present invention include peripheral nerve trauma and toxin-induced peripheral neuropathies. Alternatively, a composition of polyclonal IgGs can be applied directly to a peripheral nerve cell to induce maturation, differentiation into a myelinating state, and myelin expression or promote cell survival.
    Type: Grant
    Filed: October 30, 2017
    Date of Patent: December 3, 2019
    Inventors: Patrick Küry, Nevena Tzekova, Hans-Peter Hartung, Corinna Hermann, Birgit Maria Reipert, Hans-Peter Schwarz, Hartmut Ehrlich, Sebastian Bunk
  • Publication number: 20190328747
    Abstract: An antitumor pharmaceutical combination includes (i) a compound ABX196 and (ii) at least one chemotherapeutic agent and/or at least one immunotherapeutic agent, for use in the treatment of cancer.
    Type: Application
    Filed: September 14, 2017
    Publication date: October 31, 2019
    Inventors: Sandrine CRABE, Didier SCHERRER, Hartmut EHRLICH, Philippe POULETTY
  • Patent number: 10329583
    Abstract: The present invention relates to recombinant viral vectors and methods of using the recombinant viral vectors to induce an immune response to influenza A viruses. The invention provides recombinant viral vectors based, for example, on the non-replicating modified vaccinia virus Ankara. When administered according to methods of the invention, the recombinant viral vectors are designed to be cross-protective and induce heterosubtypic immunity to influenza A viruses.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: June 25, 2019
    Assignee: OLOGY BIOSERVICES INC.
    Inventors: Falko-Günter Falkner, Birgit Schafer, P Noel Barrett, Thomas R. Kreil, Hartmut Ehrlich, Annett Hessel
  • Publication number: 20190134147
    Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, an identify a TFPI-binding compound.
    Type: Application
    Filed: January 14, 2019
    Publication date: May 9, 2019
    Applicants: BAXALTA GMBH, BAXALTA INCORPORATED
    Inventors: Michael Dockal, Rudolf Hartmann, Markus Fries, Friedrich Scheiflinger, Hartmut Ehrlich, Ulrich Reineke, Frank Osterkamp, Thomas Polakowski
  • Patent number: 10201586
    Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, an identify a TFPI-binding compound.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: February 12, 2019
    Assignees: Baxalta GmbH, Baxalta Incorporated
    Inventors: Michael Dockal, Rudolf Hartmann, Markus Fries, Friedrich Scheiflinger, Hartmut Ehrlich, Ulrich Reineke, Frank Osterkamp, Thomas Polakowski
  • Publication number: 20180291087
    Abstract: The present invention is based on the discovery of polyclonal IgG's ability to promote Schwann cell maturation, differentiation, and myelin production. Methods for treating non-idiopathic, demyelinating peripheral neuropathies in mammals, where the neuropathy is not immune-mediated or infection-mediated, through the administration of polyclonal IgG are provided. Types of demyelinating peripheral neuropathies treatable with the present invention include peripheral nerve trauma and toxin-induced peripheral neuropathies. Alternatively, a composition of polyclonal IgGs can be applied directly to a peripheral nerve cell to induce maturation, differentiation into a myelinating state, and myelin expression or promote cell survival.
    Type: Application
    Filed: October 30, 2017
    Publication date: October 11, 2018
    Inventors: Patrick Küry, Nevena Tzekova, Hans-Peter Hartung, Corinna Hermann, Birgit Maria Reipert, Hans-Peter Schwarz, Hartmut Ehrlich, Sebastian Bunk